You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Graft vs Host Disease: A Complex Disease With Complex Considerations

  • Authors: Corey S. Cutler, MD, MPH, FRCPC; Carrie L. Kitko, MD; Miguel-Angel Perales, MD
  • CME Released: 9/29/2023
  • Valid for credit through: 9/29/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, pathologists, and other clinicians who treat patients undergoing hematopoietic stem cell transplantation.

The goal of this activity is for learners to be better able to stay up to date on current and emerging data and best practices in graft vs host disease (GvHD) so they can confidently manage this condition across the disease continuum.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Epidemiology and pathophysiology of GvHD
    • Clinical trial data for GvHD therapies
  • Have greater competence related to
    • Integrating current therapies for the prevention and treatment of GvHD
    • Managing symptoms of GvHD using adjunctive/nonsystemic therapies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

-


Faculty

  • Corey S. Cutler, MD, MPH, FRCPC

    Professor of Medicine
    Harvard Medical School
    Director, Adult Stem Cell Transplantation Program
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Corey S. Cutler, MD, MPH, FRCPC, has the following relevant financial relationships:
    Consultant or advisor for: Astellas Pharma, Inc.; Bristol Myers Squibb Company; Cellarity; CSL Behring; CTI BioPharma Corp.; Equillium; Incyte Corporation; Inhibrix; Janssen Biotech, Inc.; Jasper Therapeutics, Inc.; Jazz Pharmaceuticals, Inc.; Mallinckrodt Pharmaceuticals; Omeros Corporation; Rigel Pharmaceuticals; Sanofi
    Stock options from: Cimeio Therapeutics; Oxford Immune Algorithmics
    Owns stock (publicly traded) in: Actinium Pharmaceuticals Inc; Allogene Therapeutics Inc; bluebird bio Inc ; Soligenix, Inc; Verastem Inc; 2Seventy Bio Inc.

  • Carrie L. Kitko, MD

    Associate Professor of Pediatrics
    Medical Director
    Pediatric Stem Cell Transplantation Program
    Ingram Professor of Pediatric Oncology
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Disclosures

    Carrie L. Kitko, MD, has the following relevant financial relationships:
    Consultant or advisor for: Horizon Therapeutics

  • Miguel-Angel Perales, MD

    Professor of Medicine
    Weill Cornell Medical College
    Chief, Adult Bone Marrow Transplantation Service
    Attending Physician and Member
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Miguel-Angel Perales, MD, has the following relevant financial relationships:
    Consultant or advisor for: Adicet Bio; Allogene Therapeutics Inc; AlloVir; Bristol Myers Squibb Company; CARGO Therapeutics, Inc.; Caribou Biosciences; Celgene Corporation; Equillium; ExeVir Bio; ImmPACT Bio; Incyte Corporation; Karyopharm Therapeutics; Kite Pharma, Inc./Gilead Sciences, Inc.; Merck; Miltenyi Biotec; MorphoSys; Nektar Therapeutics; Novartis; Omeros Corporation; Orca Bio; VectivBio AG; Vor Biopharma
    Research funding from: Allogene Therapeutics Inc; Incyte Corporation; Kite Pharma, Inc./Gilead Sciences, Inc.; Miltenyi Biotec; Nektar Therapeutics; Novartis
    Stock options from: NexImmune; Omeros Corporation; Orca Bio
    Other: Member, DSMB: Cidara Therapeutics; Medigene; SELLAS Life Sciences

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Graft vs Host Disease: A Complex Disease With Complex Considerations

Authors: Corey S. Cutler, MD, MPH, FRCPC; Carrie L. Kitko, MD; Miguel-Angel Perales, MDFaculty and Disclosures

CME Released: 9/29/2023

Valid for credit through: 9/29/2024, 11:59 PM EST

processing....

Select Any Chapter to Begin

  • Print